摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

| 1086534-79-3

中文名称
——
中文别名
——
英文名称
——
英文别名
——
化学式
CAS
1086534-79-3
化学式
C161H287N21O56
mdl
——
分子量
3413.16
InChiKey
FFGKBOCXOGHLFU-HRJYQDDOSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.97
  • 重原子数:
    238.0
  • 可旋转键数:
    98.0
  • 环数:
    21.0
  • sp3杂化的碳原子比例:
    0.87
  • 拓扑面积:
    1088.15
  • 氢给体数:
    35.0
  • 氢受体数:
    56.0

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Folate-Appended β-Cyclodextrin as a Promising Tumor Targeting Carrier for Antitumor Drugs in Vitro and in Vivo
    摘要:
    A large number of antitumor drug delivery carriers based on passive targeting and/or active targeting have been developed. However, encapsulation of antitumor drugs into these drug carriers is often complicated, and antitumor activities of these targeting systems are not satisfactory. In the present study, we first prepared heptakis-6-folic acid (FA)-appended beta-cyclodextrin (beta-CyD) possessing two caproic acids between FA and a beta-CyD molecule as a spacer (Fol-c(2)-beta-CyD) and evaluated the potential as a novel tumor targeting carrier for antitumor drugs through a complexation. Fol-c(2)-beta-CyD formed an inclusion complex with doxorubicin (DOX) at a 1:1 molar ratio with a markedly high stability constant (>10(6) M-1). Cellular uptake of DOX was increased by the addition of Fol-c(2)-beta-CyD in KB cells, a folate receptor-alpha (FR-alpha)-positive cell line. Additionally, Fol-c(2)-beta-CyD increased in vitro antitumor activities of antitumor drugs such as DOX, vinblastine (VBL), and paclitaxel (PTX) in KB cells, but not in A549 cells, a FR-alpha-negative cell line. The complex of DOX with Fol-c(2)-beta-CyD markedly increased antitumor activity of DOX, not only after intratumoral administration but also after intravenous administration to mice subcutaneously inoculated Colon-26 cells, a FR-alpha-positive cell line. These findings suggest that Fol-c(2)-beta-CyD could be useful as a promising antitumor drug carrier.
    DOI:
    10.1021/bc400015r
  • 作为产物:
    描述:
    全氨基倍他环糊精N-甲基吗啉4-(4,6-二甲氧基三嗪-2-基)-4-甲基吗啉盐酸盐 作用下, 以 甲醇 为溶剂, 反应 37.0h, 生成
    参考文献:
    名称:
    Folate-Appended β-Cyclodextrin as a Promising Tumor Targeting Carrier for Antitumor Drugs in Vitro and in Vivo
    摘要:
    A large number of antitumor drug delivery carriers based on passive targeting and/or active targeting have been developed. However, encapsulation of antitumor drugs into these drug carriers is often complicated, and antitumor activities of these targeting systems are not satisfactory. In the present study, we first prepared heptakis-6-folic acid (FA)-appended beta-cyclodextrin (beta-CyD) possessing two caproic acids between FA and a beta-CyD molecule as a spacer (Fol-c(2)-beta-CyD) and evaluated the potential as a novel tumor targeting carrier for antitumor drugs through a complexation. Fol-c(2)-beta-CyD formed an inclusion complex with doxorubicin (DOX) at a 1:1 molar ratio with a markedly high stability constant (>10(6) M-1). Cellular uptake of DOX was increased by the addition of Fol-c(2)-beta-CyD in KB cells, a folate receptor-alpha (FR-alpha)-positive cell line. Additionally, Fol-c(2)-beta-CyD increased in vitro antitumor activities of antitumor drugs such as DOX, vinblastine (VBL), and paclitaxel (PTX) in KB cells, but not in A549 cells, a FR-alpha-negative cell line. The complex of DOX with Fol-c(2)-beta-CyD markedly increased antitumor activity of DOX, not only after intratumoral administration but also after intravenous administration to mice subcutaneously inoculated Colon-26 cells, a FR-alpha-positive cell line. These findings suggest that Fol-c(2)-beta-CyD could be useful as a promising antitumor drug carrier.
    DOI:
    10.1021/bc400015r
点击查看最新优质反应信息